TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06264531
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections
Study: NCT06619912
Drug: Dexmedetomidine nasal spray
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be randomised to receive either dexmedetomidine or saline nasal spray (1.5ug/kg, ideal body weight) at the night before surgery and 30 minutes before induction.
Study: NCT05063851
Drug: Memantine Hydrochloride Tablets
Normalized name: Memantine Hydrochloride Tablets
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
Study: NCT06444178
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06444178
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration
Study: NCT05153525
Drug: Intermittent boluses of Cisatracurium
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
Study: NCT05153525
Drug: Intravenous infusion of Cisatracurium for 24 hours
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
Study: NCT00002247
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06747416
Drug: KN057
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KN057 will be administered subcutaneously once a week.
Study: NCT06747273
Drug: SRP-9004
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) infusion.
Study: NCT06749730
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adepelizumab ,1200mg, q3w
Study: NCT06749730
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib，250mg，QD
Study: NCT06749730
Drug: gemcitabine and cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cisplatin 25mg/m2，gemcitabine 1000mg/m2 d1,d8，q3w
Study: NCT05098847
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
Study: NCT05098847
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study: NCT06747975
Drug: Dexamethasone and Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive Caudal epidural block (0.5 mL/kg of bupivacaine 0.25% plus dexa- methasone 0.1 mg/kg plus 4mg ondansetron ), and IV 5 mL normal saline
Study: NCT06747975
Drug: Bupivacaine + saline
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive caudal epidural block (0.5 mL/kg of bupivacaine 0.25% only) and IV 5 mL normal saline
Study: NCT06747611
Drug: Vancomycin, Neomycin and MTT capsules
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.
Study: NCT06752044
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
Study: NCT06752343
Drug: Clobetasol
Normalized name: Clobetasol
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.025 CLO for 8 days~Other Names:~topical steroid administration
Study: NCT06753955
Drug: ART5803
Normalized name: ART5803
DrugBank: ART5803 (DB18379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
Study: NCT06753955
Drug: Intravenous immunoglobulin (IVIG)
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as background treatment prior to the investigational product
Study: NCT06755684
Drug: Befotertinib combined Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Befotertinib combined Bevacizumab
Study: NCT06755684
Drug: Befotertinib combined platinum-based double chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befotertinib combined platinum-based double chemotherapy
Study: NCT06752408
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
Study: NCT06147648
Drug: Tacrolimus Sustained-release Capsules
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
Study: NCT06749756
Drug: vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On the basis of the basic treatment of sepsis, intravenous vitamin C 50mg/kg q6h was given for 4 days.
Study: NCT06749756
Drug: 0.9%Nacl
Normalized name: triamcinolone acet/0.9%NaCl/PF 40 mg/mL INJECTION VIAL (ML)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The same dose of placebo (0.9% sodium chloride solution) was administered on top of the sepsis base treatment for 4 days.
Study: NCT06754865
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT06741930
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Ketamine group received IV ketamine at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
Study: NCT06741930
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The Midazolam group received IV midazolam at a titrated dose of 0.15-0.40 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
Study: NCT06741930
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Propofol group received IV propofol at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
Study: NCT06745193
Drug: chidamide+Camrelizumab+Apatinib
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chidamide+Camrelizumab+Apatinib
Study: NCT06745193
Drug: Irinotecan or Docetaxel or Paclitaxel
Normalized name: Medicated Pad or Tape
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan Docetaxel Paclitaxel
Study: NCT06753565
Drug: Carnitine
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is a nutritional supplement with trade name  Carnitol® in Egypt.
Study: NCT06756061
Drug: Prednisone + Jakavi(ruxolitinib)
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will receive ruxolitinib 10 mg orally twice daily (BID) and prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease. (However, after the 48-week mark, participants in the ruxolitinib treatment group may continue to receive ruxolitinib for an additional maximum of 2 years, based on the investigator's judgment regarding the need for ongoing treatment. The total duration of ruxolitinib administration will not exceed 3 years.)
Study: NCT06756061
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group will receive prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease.
Study: NCT06755528
Drug: Chitosan
Normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive medications for fallopian tube adhesions (Chitosan (glucosamine (GIcN) and N-acetylglucosamine (GIcNAc) units,1 tablet per day) as prescribed by the gynecologist
Study: NCT06754943
Drug: Treatment B_Period 2
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Study: NCT06754943
Drug: Treatment A_Period 2
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Study: NCT05393076
Drug: Linerixibat
Normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linerixibat dose and administration as per study intervention.
Study: NCT06754943
Drug: Treatment B_Period 3
Normalized name: 3'-Deoxykanamycin B
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Study: NCT06754943
Drug: Treatment A_Period 4
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Study: NCT06753721
Drug: Doxorubicin liposome combined with CapOX and Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (7.5 mg/kg, IV, Day 1) + Oxaliplatin (130 mg/m², IV, Day 1) + Capecitabine (1000 mg/m², oral, twice daily, for 14 days) + Doxorubicin liposome (20 mg/m², IV, Day 1), repeated every 3 weeks.
Study: NCT06753890
Drug: Changkang granules
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
Study: NCT06756308
Drug: Enasidenib
Normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enasidenib 100 mg daily on 28-day cycles.
Study: NCT06756308
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter
Study: NCT06751992
Drug: Conversion to extended-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment
Study: NCT06751992
Drug: Maintenance of immediate-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment
Study: NCT06755346
Drug: Cannabis plant (THC 20mg)
Normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
Study: NCT06755346
Drug: Cannabis (0%/ THC / 0% CBD)
Normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (0%) / CBD (0%) - Placebo marijuana
Study: NCT06755346
Drug: Cannabis plant (THC 40mg)
Normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
Study: NCT06754644
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 on Day 1 of each 21-day cycle of the study
Study: NCT06754644
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles
Study: NCT06755671
Drug: Danning Tablet
Normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danning Tablet is the only exposure in this observational study.
Study: NCT04936711
Drug: Marcaine
Normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marcaine spray at incision site after closure
Study: NCT06738043
Drug: Dexmedetomidine infusion
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg/kg/h until 10 minutes before the end of surgery.
Study: NCT06738043
Drug: Ketamine infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg/kg/h until 10 minutes before the end of surgery.
Study: NCT06738043
Drug: Normal Saline Infusion (Placebo)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.
Study: NCT06738017
Drug: BMN 349
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg oral tablet
Study: NCT06766864
Drug: DR-01
Normalized name: DR-01
DrugBank: DR-01 (DB18258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR-01 is a monoclonal antibody
Study: NCT06766474
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to our knowledge, this study is the 1st to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus subcutaneous infiltration for postoperative donor site pain control for patients undergoing STSG procedures.
Study: NCT06764186
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
Study: NCT06764186
Drug: Capivasertib
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Study: NCT06769412
Drug: aflibercept 2 mg
Normalized name: aflibercept 2 MG in 0.05 ML Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No study-specific investigations for this descriptive observational study
Study: NCT05748587
Drug: Deferoxamine
Normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular deferoxamine (200 mg/kg) injection to rats
Study: NCT06767774
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * pitavastatin 4mg~* ezetimibe 10mg
Study: NCT06764615
Drug: Zasocitinib
Normalized name: Zasocitinib
DrugBank: Zasocitinib (DB19278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zasocitinib capsules.
Study: NCT06409819
Drug: control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants assigned to the control arm will start a 7-day course of intravenous sterile normal saline (placebo) administered twice daily.
Study: NCT05632926
Drug: 40 mg CBL-514
Normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBL-514 will be administered at the raised area of cellulite.
Study: NCT05632926
Drug: 60 mg CBL-514
Normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBL-514 will be administered at the raised area of cellulite.
Study: NCT05632926
Drug: 80 mg CBL-514
Normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBL-514 will be administered at the raised area of cellulite.
Study: NCT06247410
Drug: Rotigotine 8Mg/24Hrs Patch
Normalized name: ROTIGOTINE 8MG/24HRS PATCH
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days
Study: NCT05338931
Drug: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD19 Chimeric Antigen Receptor T cell
Study: NCT05069350
Drug: bupivacaine 0.5% and oxubuprocaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: using each drug as surface anesthesia before intravitreal injections
Study: NCT05080569
Drug: Progesterone Vaginal Product
Normalized name: progesterone Vaginal Product
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3dd200mg
Study: NCT04642365
Drug: RO7296682
Normalized name: RO7296682
DrugBank: RO7296682 (DB17531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7296682 will be administered as per the schedules specified in the respective arms.
Study: NCT04642365
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.
Study: NCT05727098
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of Bupivacaine 0.25% in ESPB
Study: NCT05727098
Drug: Bupivacaine Hydrochloride and dexmedetomedine
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
Study: NCT05727098
Drug: Bupivacaine Hydrochloride and ketamine
Normalized name: Ketamine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of Bupivacaine 0.25% and ketamine in ESPB
Study: NCT05643872
Drug: PTX-022
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QTORIN rapamycin 3.9% anhydrous gel
Study: NCT00255554
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06387134
Drug: Lifei Xiaoji Wan
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Lifei Xiaoji Wan consists of ginseng, blackhead,rhubarb, aster, forehu, and thin on.
Study: NCT06081673
Drug: Penpulimab injection
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
Study: NCT06081673
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin :75mg/m2, D1, IV(21 days/cycle)
Study: NCT06081673
Drug: albumin-paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
Study: NCT06760533
Drug: Psilocybin 25 mg
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 25 mg (active treatment) administered during the psychotherapy treatment session.
Study: NCT06760533
Drug: Niacin 100 mg
Normalized name: niacin 100 MG
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 100 mg (placebo) administered during the psychotherapy treatment session.